COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study

JAAD Int. 2022 Sep:8:31-33. doi: 10.1016/j.jdin.2022.03.011. Epub 2022 Mar 28.

Authors

Di Yan¹, Avani M Kolla¹, Trevor Young¹, Lauren Fried¹, Shruthi Shankar¹, Lauren Rangel¹, Lu Yin¹, Rochelle Castillo², Alexa Steuer¹, Katerina Svigos¹, Peter Izmirly², Vaish Sekar², Robert Lesser², Gary Solomon², Rebecca B Blank², Rebecca H Haberman², Andrea L Neimann¹, Jose U Scher²

Affiliations

¹ Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
² Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, New York.

No abstract available

Keywords: COVID-19; coronavirus; immune-mediated inflammatory disease; immunomodulators; psoriasis; psoriatic arthritis.

Grants and funding

T32 AR069515/AR/NIAMS NIH HHS/United States